KANAMYCIN
Description Sources- Product Name
- KANAMYCIN
- CAS No.
- 59-01-8
- Chemical Name
- KANAMYCIN
- Synonyms
- KANAMYCIN A;kanamicina;KanamycinMonosulfateA;o-6-deoxy-alpha-d-glucopyranosyl-(1.fwdarw.)]-2-deoxy-;d-xydi;KANAMYCIN;d-deoxydi;Kanamycins;Kanamycine;KANAMYCIN BASE
- CBNumber
- CB2402286
- Molecular Formula
- C18H36N4O11
- Formula Weight
- 484.5
- MOL File
- 59-01-8.mol
KANAMYCIN Property
- Melting point:
- >175°C (dec.)
- alpha
- D24 +146° (0.1N H2SO4)
- Boiling point:
- 581.13°C (rough estimate)
- Density
- 1.4042 (rough estimate)
- refractive index
- 1.6700 (estimate)
- storage temp.
- 2-8°C
- solubility
- Methanol (Slightly, Sonicated), Water (Slightly)
- form
- liquid
- pka
- pKa 6.40/7.55/8.40/9.40(H2O) (Uncertain)
- color
- White to Off-White
- EPA Substance Registry System
- D-Streptamine, O-3-amino-3-deoxy-.alpha.-D-glucopyranosyl-(1.fwdarw.6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1.fwdarw.4)]-2-deoxy- (59-01-8)
Safety
- WGK Germany
- 2
- Hazardous Substances Data
- 59-01-8(Hazardous Substances Data)
- Toxicity
- LD50 i.v. in mice: 583 mg/kg (Wakazawa)
N-Bromosuccinimide Price
- Product number
- 16140
- Product name
- Kanamycin A
- Purity
- ≥95%
- Packaging
- 1g
- Price
- $25
- Updated
- 2021/12/16
- Product number
- 16140
- Product name
- Kanamycin A
- Purity
- ≥95%
- Packaging
- 5g
- Price
- $88
- Updated
- 2021/12/16
- Product number
- 16140
- Product name
- Kanamycin A
- Purity
- ≥95%
- Packaging
- 10g
- Price
- $138
- Updated
- 2021/12/16
- Product number
- 16140
- Product name
- Kanamycin A
- Purity
- ≥95%
- Packaging
- 25g
- Price
- $219
- Updated
- 2021/12/16
- Product number
- 257328
- Product name
- Kanamycin A
- Packaging
- 1g
- Price
- $322
- Updated
- 2021/12/16
KANAMYCIN Chemical Properties,Usage,Production
Description
Kanamycin is a well-known bactericidal antibiotic. It belongs to the aminoglycoside antibiotic group. It can be used for the treatment of various pathogens including E. coli, Proteus species (both indole-positive and indole-negative), Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens and Acinetobacter species1-4. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate5. Aminoglycoside-type drug take actions through “irreversibly” binding to the 30S subunit of the ribosome, further blocking the protein synthesis. Kanamycin kills bacteria cells binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes5.
Sources
- Pindell, M. H. "The pharmacology of kanamycin--a review and new developments." Annals of the New York Academy of Sciences 132.2(1966): 805–810.
- https://www.annualreviews.org/doi/pdf/10.1146/annurev.bi.42.070173.002351
- Spelman, D. W., M. Mcdonald, and W. J. Spicer. "Aminoglycoside antibiotic agents: a review." Medical Journal of Australia 151.6(1989): 346.
- https://en.wikipedia.org/wiki/Kanamycin_A
- https://www.drugbank.ca/drugs/DB01172
Uses
Kanamycin A is an antibiotic complex produced by Streptomyces kanamyceticus Okami & Umezawa from Japanese soil. Comprised of three components, kanamycin A, the major component, and kanamycins B and C, two minor congeners. Antibacterial.
Uses
Antibacterial Kantrex (Apothecon).
Indications
Kanamycin, O-3-amino-3-deoxy-α-D-glucopyranosyl-(1→6)-O-[6-deoxy-
6-amino-α-D-glucopyranosyl-(1→4)]–2-deoxy-D-streptamine (32.4.6), is isolated from a
culture fluid of the actinomycete Streptomyces kanamyceticus, which produces three
antibiotics—kanamycins A, B, and C.
Kanamycin A is similar to streptomycin and neomycines, and it possesses a broad spectrum of antimicrobial action. It is active with respect to most Gram-positive and Gramnegative microorganisms (staphylococci, colon bacillus, klebisella, Fridlender’s bacillus,
proteus, shigella, salmonella).
It is used to treat sepsis, meningitis, osteomyelitis, peritonitis, pneumonia, pyelonephritis, pyelocystitis, infected wounds, and post-operational, purulent complications that are
caused by microorganisms sensitive to this drug. Kanamycin is used to treat tuberculosis
of the lungs and other organs upon resistance to other antituberculosis drugs. Synonyms of
this drug are karmycin, kamaxin, resistomycin, and many others.
Definition
ChEBI: Kanamycin A is a member of kanamycins. It has a role as a bacterial metabolite. It is a conjugate base of a kanamycin A(4+).
brand name
Klebcil (King).
Antimicrobial activity
It is active against staphylococci, including methicillin-resistant strains. Other aerobic and anaerobic Gram-positive cocci and most Gram-positive rods are resistant, but M. tuberculosis is susceptible. It is widely active against most aerobic Gram-negative rods, except Burkholderia cepacia and Sten. maltophilia. Treponema pallidum, Leptospira and Mycoplasma spp. are all resistant.
Acquired resistance
Resistance is usually plasmid borne and due to enzymatic inactivation of the drug by enzymes that also inactivate gentamicin or tobramycin . Resistance due to reduced permeability is also encountered.
Pharmacokinetics
Cmax 500 mg intramuscular： c.15–20 mg/L after 1 h
Plasma half-life: 2.5 h
Volume of distribution: 0.3 L/kg
Plasma protein binding: Low
Absorption and distribution
Very little is absorbed from the intestinal tract. The peak plasma
concentration in the neonate is dose related: concentrations of
8–30 mg/L (mean 18 mg/L) have been found 1 h after a 10 mg/kg
dose. The drug is confined to the extracellular fluid. The concentration
in serous fluids is said to equal that in the plasma,
but it does not enter the CSF in therapeutically useful concentrations
even in the presence of meningeal inflammation.
Excretion
It is excreted almost entirely by the kidneys, almost exclusively
in the glomerular filtrate. Up to 80% of the dose appears
unchanged in the urine over the first 24 h, producing concentrations
around 100–500 mg/L. It is retained in proportion to
reduction in renal function. Less than 1% of the dose appears
in the bile. In patients receiving 500 mg intramuscularly preoperatively,
concentrations of 2–23 mg/L have been found in
bile and 8–14 mg/kg in gallbladder wall.
Clinical Use
Formerly used for severe infection with susceptible organisms, it has largely been superseded by other aminoglycosides.
Side effects
Intramuscular injections are moderately painful, and minor
side effects similar to those encountered with streptomycin
have been described. Eosinophilia in the absence of other manifestations of allergy occurs in up to 10% of patients.
Other manifestations of hypersensitivity are rare.
As with other aminoglycosides, the most important toxic
effects are on the eighth nerve and much less frequently on
the kidney. Renal damage is seen principally in patients with
pre-existing renal disease or treated concurrently or sequentially
with other potentially nephrotoxic agents. The drug
accumulates in the renal cortex, producing cloudy swelling,
which may progress to acute necrosis of proximal tubular
cells with oliguric renal failure. Less dramatic deterioration
of renal function, particularly exaggeration of the potential
nephrotoxicity of other drugs or of existing renal disease, is
of principal importance because it increases the likelihood of
ototoxicity.
Vestibular damage is uncommon but may be severe and
prolonged. Hearing damage is usually bilateral, and typically
affects frequencies above the conversational range. Acute toxicity
is most likely in patients in whom the plasma concentration
exceeds 30 mg/L, but chronic toxicity may be seen in patients
treated with the drug over long periods. Auditory toxicity may
be potentiated by concurrent treatment with potent diuretics
like ethacrynic acid. If tinnitus – which usually heralds the onset
of auditory injury – develops, the drug should be withdrawn.
Neuromuscular blockade is seen particularly in patients
receiving other muscle relaxants or suffering from myasthenia
gravis and may be reversed by neostigmine.
KANAMYCIN Preparation Products And Raw materials
Raw materials
Preparation Products
KANAMYCIN Suppliers
- Tel
- 15337215803 15337215803
- Fax
- 027-89771658
- 3357312443@qq.com
- Country
- China
- ProdList
- 233
- Advantage
- 56
- Tel
- 0531-88773586 13210588999
- Fax
- 053188773586
- 304264064@qq.com
- Country
- China
- ProdList
- 193
- Advantage
- 58
- Tel
- 15105138935 15105138935
- 2622104407@qq.com
- Country
- China
- ProdList
- 45
- Advantage
- 58
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Country
- United States
- ProdList
- 14059
- Advantage
- 65
- Tel
- (0086)755-61930359 (0086)18038192047
- Fax
- (0086)755-84556470
- jo@pharmade.com
- Country
- China
- ProdList
- 279
- Advantage
- 58
- Tel
- 27-81302488 18007166089
- Fax
- 027-81302088
- info@dkybpc.com
- Country
- China
- ProdList
- 2024
- Advantage
- 58
- Tel
- 0755-66853366 13670046396
- Fax
- 0755-28363542
- sales@chem-strong.com
- Country
- China
- ProdList
- 17982
- Advantage
- 56
- Tel
- 027-87465837 19945049750
- Fax
- 027-8777-2287
- sales@finetechnology-ind.com
- Country
- China
- ProdList
- 9533
- Advantage
- 58
- Tel
- 027-59262863 13277907145 3091977954
- Fax
- 027-59420980
- Country
- China
- ProdList
- 4951
- Advantage
- 58
- Tel
- 027-59420981,18702770802
- Fax
- 027-83322098
- Country
- China
- ProdList
- 1975
- Advantage
- 50
View Lastest Price from KANAMYCIN manufacturers
- Product
- KANAMYCIN 59-01-8
- Price
- US $1.00-1.00/KG
- Min. Order
- 1g
- Purity
- 99%
- Supply Ability
- 50tons
- Release date
- 2020-05-07
- Product
- Kanamycin 59-01-8
- Price
- US $0.00/KG
- Min. Order
- 1KG
- Purity
- 99%
- Supply Ability
- 50000KG/month
- Release date
- 2023-09-08
- Product
- Kanamycin 59-01-8
- Price
- US $1.90/KG
- Min. Order
- 1KG
- Purity
- 99%
- Supply Ability
- 10 ton
- Release date
- 2021-08-09